Topological patterns of damage and compensation in chronic neuroinflammation

B05

Although research has made significant progress, there are still mechanistic factors that markedly influence disease progression and compensation reserve, making an accurate prognosis of sub-group and individual disease courses in MS extremely challenging. We aim at elaborating the framework for the automatic stratification of disease courses and therapeutic responses. Using advanced magnetic resonance imaging (MRI) together with brain networks phenotyping and immune response analyses, we aim to early recognize patients at high risk for disease progression (i.e. evolving functional impairment) or with insufficient therapeutic responses to immunomodulation:

    1. Can the acute individual network response help to predict future relapses and long-term disease trajectories?
    2. What is the difference in chronic network responses between patients with continuous functional worsening compared to clinically stable patients?
    3. How do the predictive differences of grey matter (GM) and white matter (WM) lesion localization impact on network dynamics and disease progression?
    4. What is the role of cortical lesions and their corresponding dynamics (enlarging, smoldering lesions) for WM and GM network reorganization and evolving functional impairment?
    5. Can peripheral immunological markers be linked to data from MRI network analysis to improve the understanding of the pathomechanisms underlying network reorganization in MS?

 

 

 

 

 

 

 

 

 

 

 

Principal Investigators:

Prof. Dr. med. Sergiu Groppa
Klinik für Neurologie
Mainz
segroppa@uni-mainz.de

Prof. Dr.-Ing. Muthuraman Muthuraman
Klinik für Neurologie
Mainz
mmuthura@uni-mainz.de

Univ.-Prof. Dr. med. Dr. rer. nat. Dr. h.c. Sven G. Meuth
Klinik für Neurologie
Düsseldorf
sven.meuth@med.uni-duesseldorf.de

News

Thu, 28/01/2021
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced the publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in the peer-reviewed journal Science. The publication titled “A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis” co-authored by SFB principal investigator Ari Waisman summarizes the findings on the disease-suppressing effects […]...more
Wed, 20/01/2021
A new study on neurological manifestations of severe COVID-19 reveals nervous system immune deficiency
Patients suffering from COVID-19 can develop concomitant and long-term symptoms in their nervous system. The most common symptom in this context is the loss of the sense of smell and taste, while more severe symptoms such as stroke, cerebral seizures, or meningitis are possible. A team of scientists from the medical faculties at the Universities […]...more
Fri, 15/01/2021
Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity
It has long been acknowledged that multiple sclerosis disease risk is associated with reduced sun-exposure, and subsequent low vitamin D levels. The study by Ostkamp et al. now assessed the relationship between measures of sun exposure and MS severity. For this, the researchers analyzed data of around 2,000 patients from the German NationMS- and the […]...more